(NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte™ in patients with cutaneous ...
As ORDI holders seek refuge in Kava for its reputation as a stable blockchain solution, another name has been making waves in the crypto community – Lightchain AI. While Kava offers a trusted ...